Cognate started being prepped for expanded capacity when new clean rooms started arriving in 2015 after good news was turned into bad according to NWBO. In 2021 Cognate suddenly anticipated a need to double manufacturing capacity ASAP after DCVax-L Phase 3 data lock and a likely NDA early look at anticipated demand for US and Canada with potential rGBM demand added in because of rGBM endpoint changes by NWBO. Then Charles Rivers Labs took over one month later and looked to expand even further around the time talk about SOC and Project Orbis was picking up. Yes we have been talking about manufacturing for a while but nothing all that serious about Merck until Roger Perlmutter was seen at an NWBO presentation and then Dr Duffy joined NWBO during the time they would have been working on the revised SAP which was not 6 years ago. The correlation seems to be endpoint changes, SOC and Project Orbis talk that created an anticipatory demand to be prepared. Not hard to see this if looking in the right direction. Best wishes.
Market Data 
Markets 
AI
